Stockscreener 앱 받기
20.43
4.72%
0.92
시간 외 거래:
23.00
2.57
+12.58%
Uniqure N V 주식(QURE)의 최신 뉴스
(QURE) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
Wall Street Has a Positive Outlook on uniQure N.V. (QURE) Despite Challenges From The FDA - MSN
QURE INVESTIGATION: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm - GlobeNewswire Inc.
QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors With Significant Losses to Contact the Firm - NewMediaWire
Stifel Maintains uniQure N.V. (QURE) Buy Recommendation - Nasdaq
QURE Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors With Significant Losses to Contact the Firm - NewMediaWire
uniQure (NASDAQ:QURE) Price Target Lowered to $40.00 at Stifel Nicolaus - MarketBeat
Roku To Rally More Than 28%? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga
uniQure (QURE) Price Target Lowered by Stifel Analyst | QURE Sto - GuruFocus
QURE Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm - PR Newswire
Stempoint Capital LP Has $7.98 Million Stock Holdings in uniQure N.V. $QURE - MarketBeat
Mizuho Maintains uniQure N.V. (QURE) Outperform Recommendation - Nasdaq
Mizuho Lowers Price Target for uniQure (QURE) to $33.00 | QURE S - GuruFocus
Mizuho Securities Maintains UniQure NV(QURE.US) With Buy Rating, Maintains Target Price $33 - 富途牛牛
Swiss National Bank Makes New Investment in uniQure N.V. $QURE - MarketBeat
uniQure NV (HAM:UQ1) Non Operating Income : €-3.54 Mil (TTM As of Sep. 2025) - GuruFocus
uniQure NV (HAM:UQ1) Asset Impairment Charge : €0.00 Mil (TTM As of Sep. 2025) - GuruFocus
uniQure NV (HAM:UQ1) Total Long-Term Liabilities : €476.27 Mil (As of Sep. 2025) - GuruFocus
Voss Capital LP Takes $1.74 Million Position in uniQure N.V. $QURE - MarketBeat
Pale Fire Capital SE Boosts Stake in uniQure N.V. $QURE - MarketBeat
Progress on AMT-130 Halts uniQure N.V.’s (QURE) Downtrend - Insider Monkey
uniQure (NASDAQ:QURE) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
7 Hidden Multibagger Stocks to Invest In - Insider Monkey
Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec-drlb) Over Five Years – Company AnnouncementFT.com - Financial Times
Aug Wrap: Can uniQure NV stock surprise with earnings upside2025 Key Highlights & Smart Swing Trading Techniques - BỘ NỘI VỤ
uniQure (NASDAQ:QURE) Shares Down 5.1%Here's What Happened - MarketBeat
QURE Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm - Your Wyoming Link
QURE Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors With Significant Losses to Contact the Firm - NewMediaWire
uniQure (NASDAQ:QURE) Receives "Buy" Rating from Chardan Capital - MarketBeat
uniQure (NASDAQ:QURE) Shares Gap DownHere's What Happened - MarketBeat
How uniQure N.V. (UQ1) stock benefits from digital adoptionTrade Ideas & Scalable Portfolio Growth Methods - Newser
How strong is uniQure N.V. stock revenue growthJuly 2025 Sentiment & Scalable Portfolio Growth Ideas - Newser
uniQure (QURE) Is Down 17.3% After FDA Questions AMT-130 Data Sufficiency For BLAHas The Bull Case Changed? - simplywall.st
Chardan Capital Maintains uniQure N.V. (QURE) Buy Recommendation - Nasdaq
QURE Investigation Alert: Kessler Topaz Meltzer & Check, LLP Enc - GuruFocus
uniQure (QURE) Stock: Navigates Regulatory Hurdles for AMT-130 as FDA Requests Further Engagement - parameter.io
uniQure (QURE) Analyst Ratings: Chardan Capital Maintains Buy Ra - GuruFocus
Why uniQure Stock Is Trading Lower After FDA Meeting Update - Sahm
uniQure N.V. (QURE): A Bear Case Theory - Finviz
UniQure stock falls after FDA's notes on pre-application of AMT-130 - MSN
uniQure (QURE) Shares Plunge 20% on FDA Feedback for AMT-130 - GuruFocus
uniQure says FDA announced Phase I/II AMT-130 data unlikely to support BLA - TipRanks
uniQure stock falls after FDA signals data unlikely to support AMT-130 approval - Investing.com Australia
uniQure stock falls after FDA's notes on pre application of AMT-130 - Seeking Alpha
uniQure (QURE) Reassesses Strategy After FDA Feedback on AMT-130 Application - GuruFocus
UniQure Seeks US FDA Follow-Up Meeting After Being Told Data Do Not Support BLA Submission - marketscreener.com
Why Is UniQure Stock Falling In Pre-market? - Nasdaq
uniQure Faces Setback in Gene Therapy Approval - TipRanks
uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease - The Manila Times
uniQure N.V. Provides Regulatory Update on AMT-130 for Huntington's Disease - TradingView — Track All Markets
Uniqure N.V. Provides Regulatory Update on Amt-130 for Huntington's Disease - marketscreener.com
uniQure (NASDAQ: QURE) receives FDA minutes on AMT-130 BLA path for Huntington’s disease - Stock Titan
uniQure N.V. $QURE Stake Reduced by Schroder Investment Management Group - MarketBeat
uniQure N.V. $QURE Shares Acquired by JPMorgan Chase & Co. - MarketBeat
0.36%
1.05%
자본화:
|
볼륨(24시간):